Literature DB >> 23233590

Delayed opportunistic infections in hematopoietic stem cell transplantation patients: a surmountable challenge.

Kieren A Marr1.   

Abstract

Changes in the transplantation procedure and the implementation of effective supportive care strategies have decreased the incidence of infectious complications early after conditioning therapy for allogeneic hematopoietic stem cell transplantation (HCT) and have extended the duration of risks later. Therefore, the types of infections that cause significant morbidity and the timing of risks have changed. These late infections are caused by all types of organisms, bacterial, viral, and fungal, but risks are predictable and surmountable with the use of tailored prevention strategies. Specifically, recent studies document prolonged risks for bacterial infections in the setting of GVHD, especially those caused by encapsulated organisms and those secondary to impaired Ab responses. Both prophylaxis and vaccination strategies can be used as a means to prevent infections, which typically manifest in the respiratory tract. Multiple viruses cause infection later after HCT, including several herpesviruses (eg, CMV and varicella zoster virus) and other respiratory viruses such as influenza and adenovirus. These infections can cause severe disease with diagnostic challenges, but prevention strategies using enhanced monitoring and/or prophylaxis may be effective. Finally, fungi also cause disease late after HCT, especially filamentous fungi (eg, Aspergillus species and Mucormycoses) and Pneumocystis jiroveci; prophylactic strategies may be used successfully to prevent invasive infection. Late infections and methods to prevent them are reviewed herein.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233590      PMCID: PMC4696052          DOI: 10.1182/asheducation-2012.1.265

Source DB:  PubMed          Journal:  Hematology Am Soc Hematol Educ Program        ISSN: 1520-4383


  48 in total

1.  High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation.

Authors:  M Mohty; C Faucher; N Vey; A M Stoppa; F Viret; I Chabbert; C Chabannon; R Bouabdallah; P Ladaique; L Collet; C Zandotti; D Maraninchi; D Blaise
Journal:  Bone Marrow Transplant       Date:  2000-08       Impact factor: 5.483

2.  BK DNA viral load in plasma: evidence for an association with hemorrhagic cystitis in allogeneic hematopoietic cell transplant recipients.

Authors:  Veronique Erard; Hyung Woo Kim; Lawrence Corey; Ajit Limaye; Meei-Li Huang; David Myerson; Chris Davis; Michael Boeckh
Journal:  Blood       Date:  2005-04-21       Impact factor: 22.113

3.  The benefit of influenza vaccination after bone marrow transplantation.

Authors:  C M Machado; M R A Cardoso; I F da Rocha; L S V Boas; F L Dulley; C S Pannuti
Journal:  Bone Marrow Transplant       Date:  2005-11       Impact factor: 5.483

4.  Influenza infections after hematopoietic stem cell transplantation.

Authors:  Clarisse M Machado
Journal:  Clin Infect Dis       Date:  2005-07-15       Impact factor: 9.079

5.  Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.

Authors:  Andrew J Ullmann; Jeffrey H Lipton; David H Vesole; Pranatharthi Chandrasekar; Amelia Langston; Stefano R Tarantolo; Hildegard Greinix; Wellington Morais de Azevedo; Vijay Reddy; Navdeep Boparai; Lisa Pedicone; Hernando Patino; Simon Durrant
Journal:  N Engl J Med       Date:  2007-01-25       Impact factor: 91.245

Review 6.  Nocardial infections in bone marrow transplant recipients.

Authors:  C Chouciño; S A Goodman; J P Greer; R S Stein; S N Wolff; J S Dummer
Journal:  Clin Infect Dis       Date:  1996-11       Impact factor: 9.079

7.  Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation--a randomized double-blind placebo-controlled study.

Authors:  Michael Boeckh; Hyung W Kim; Mary E D Flowers; Joel D Meyers; Raleigh A Bowden
Journal:  Blood       Date:  2005-11-10       Impact factor: 22.113

8.  Streptococcus pneumoniae infections in 47 hematopoietic stem cell transplantation recipients: clinical characteristics of infections and vaccine-breakthrough infections, 1989-2005.

Authors:  Souad Youssef; Gilhen Rodriguez; Kenneth V Rolston; Richard E Champlin; Issam I Raad; Amar Safdar
Journal:  Medicine (Baltimore)       Date:  2007-03       Impact factor: 1.889

9.  Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs.

Authors:  Peter Iliades; Steven R Meshnick; Ian G Macreadie
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

10.  Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case-control study.

Authors:  Dario Sangiolo; Barry Storer; Richard Nash; Lawrence Corey; Chris Davis; Mary Flowers; Robert C Hackman; Michael Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2005-07       Impact factor: 5.742

View more
  19 in total

1.  Current issues in transplant infectious diseases.

Authors:  Nicole Theodoropoulos; Michael G Ison
Journal:  Curr Infect Dis Rep       Date:  2013-12       Impact factor: 3.725

2.  Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin.

Authors:  Rahul Palchaudhuri; Borja Saez; Jonathan Hoggatt; Amir Schajnovitz; David B Sykes; Tiffany A Tate; Agnieszka Czechowicz; Youmna Kfoury; Fnu Ruchika; Derrick J Rossi; Gregory L Verdine; Michael K Mansour; David T Scadden
Journal:  Nat Biotechnol       Date:  2016-06-06       Impact factor: 54.908

Review 3.  Immunotherapy for opportunistic infections: Current status and future perspectives.

Authors:  Shigeo Fuji; Jürgen Löffler; Hermann Einsele; Markus Kapp
Journal:  Virulence       Date:  2016-07-06       Impact factor: 5.882

4.  Zoster prophylaxis after allogeneic hematopoietic cell transplantation using acyclovir/valacyclovir followed by vaccination.

Authors:  Kareem Jamani; Judy MacDonald; Martin Lavoie; Tyler S Williamson; Christopher B Brown; Ahsan Chaudhry; Victor H Jimenez-Zepeda; Peter Duggan; Jason Tay; Douglas Stewart; Andrew Daly; Jan Storek
Journal:  Blood Adv       Date:  2016-11-30

Review 5.  Preventing stem cell transplantation-associated viral infections using T-cell therapy.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Immunotherapy       Date:  2015-08-07       Impact factor: 4.196

Review 6.  Critically ill allogeneic hematopoietic stem cell transplantation patients in the intensive care unit: reappraisal of actual prognosis.

Authors:  C Saillard; D Blaise; D Mokart
Journal:  Bone Marrow Transplant       Date:  2016-04-04       Impact factor: 5.483

7.  Defective pulmonary innate immune responses post-stem cell transplantation; review and results from one model system.

Authors:  Racquel Domingo-Gonzalez; Bethany B Moore
Journal:  Front Immunol       Date:  2013-05-24       Impact factor: 7.561

Review 8.  Accelerating immune reconstitution after hematopoietic stem cell transplantation.

Authors:  Ifigeneia Tzannou; Ann M Leen
Journal:  Clin Transl Immunology       Date:  2014-02-28

Review 9.  Modulation of Immunoregulatory Properties of Mesenchymal Stromal Cells by Toll-Like Receptors: Potential Applications on GVHD.

Authors:  Bruno Sangiorgi; Rodrigo Alexandre Panepucci
Journal:  Stem Cells Int       Date:  2016-09-21       Impact factor: 5.443

Review 10.  Clinical Microbiology in the Intensive Care Unit: Time for Intensivists to Rejuvenate this Lost Art.

Authors:  Isabella Princess; Rohit Vadala
Journal:  Indian J Crit Care Med       Date:  2021-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.